Flerie AB (publ) (FLERIE) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

So, welcome old and new shareholders alike, analysts, media, and all who have shown an interest in FLIRI's Q2 2024 report. What an exhilarating quarter it has been, as you can see from this picture, where four of our top five shareholders were represented. That's Cayelo, the fourth AP fund, myself, and of course, Tomas Eldred. We really did crown the quarter with the ringing of the bell at Nasdaq Stockholm on the 27th of June. That is a date I will always remember. A big thanks to the team and to our advisors for making this happen. We will tell you more about this today, but first let's take a step back and introduce Fleury. because I think, in fact, this is, of course, our very first quarterly report presentation as a listed company, and maybe some of you in the audience are not as familiar with us as others, so let us start there. But first of all, the usual disclaimer, which I'm sure you're all aware of, and please act accordingly. Let me start by saying there is a biotech challenge. The biotech challenge is that even though you can make very significant money in this space. And of course, Fleury is in this space. It is a long and tricky road to success, especially for any singular biotech company. So on this slide, you see a typical journey for the development and commercialization of pharmaceutical innovation or even pharmaceutical services innovation. And there are four main challenges that I'd like to highlight. so firstly it's very hard to evaluate projects in this highly specialized sector also a large capital need is required through a very long development phase and thirdly every step of the way every new stage in this development comes with different risks and you need different people to assess and mitigate those risks so you really need to have a netwo...